Bicara Therapeutics Inc. (BCAX)
Develops antibody drugs that fight solid tumors by combining two therapeutic functions
$26.88-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+155.3%
The outlook
BCAX is trading near its 52-week highs, well above its longer-term moving averages, signaling upward momentum in the price trend. Analyst coverage leans optimistic, with an average price target about 17% above the current level. The stock sits in the upper portion of its yearly range, reflecting recent strength.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range81% of the way from its 52-week low to high
Price targetAvg target +17% vs current price
Analyst price target
~12-month · 13 analysts$31.46average target+17.0% vs now
Now $26.88
Low $16.00High $46.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.77B
52-wk high
$30.99
52-wk low
$9.57
50-day avg
$24.45
200-day avg
$19.75
Trailing P/E
—